Artificial Intelligence Expert Neil Sahota Joins Evoke Neuroscience Executive Advisory Board
NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor, United Nations Artificial Intelligence (AI) Subject Matter Expert, and UC Irvine Professor Neil…
Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosis
NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke Neuroscience, a medical device company developing and commercializing technologies to aid in diagnosis of cognitive disorders, announced today initial enrollment…
Allied : Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD Patients
Allied Corp. (OTC Pink: ALID) (“Allied”), an international medical cannabis production company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce its signing of a Letter…
Evoke Neuroscience takes on TBI, PTSD with the US Air Force
NEW YORK CITY, NY, USA, September 10, 2019 /EINPresswire.com/ — Evoke Neuroscience has been awarded a working contract by the United States Air Force (USAF) for its diagnostic device, the…
Evoke Neuroscience to Present at ROTH Capital Conference
Evoke Neuroscience announces it has been selected to present to the attendees of this year’s ROTH Capital Conference on March 18 in Orange County, California. Evoke will present its eVox®…
Evoke Neuroscience awarded People’s Choice Award at OCTANe’s Medical Technology Innovation Forum
NEW YORK, NEW YORK, USA, November 8, 2018 /EINPresswire.com/ – Evoke Neuroscience won the popular vote by attendees and took home the People’s Choice Award at OCTANe’s 13th Annual Medical…
Evoke Neuroscience to present at OCTANe’s 13th Annual Medical Technology Innovation Forum
NEW YORK, NY, USA, October 11, 2018 /EINPresswire.com/ – Evoke Neuroscience announces it has been selected to present to the attendees of this year’s Medical Technology Innovation Forum on October…
Evoke Neuroscience awarded Breakthrough Technology agreement with Premier
New York, NY, March 29, 2018 – Evoke Neuroscience has been awarded a group purchasing agreement as a breakthrough technology with Premier. Effective March 1, 2018, the agreement allows Premier…
Evoke Neuroscience announces award of VA contract for the eVox® System
Evoke Neuroscience, Inc. is pleased to announce the award of a Veterans Health Administration Contract for the eVox® System. The Contract award #36F79718D0348 enables the VA and other federal organizations…
CISION iREACH
CISION iREACH – September 14, 2017 Evoke Neuroscience named to Inc. 5000 List of America’s Fastest-Growing Private Companies for Second Consecutive Year. Read the Full Article
The eVox system is a Class II medical device that has received Section 510(K) clearance from the FDA. It is intended for the acquisition, display, and storage, of electrical activity of a patient’s brain including electroencephalograph (EEG) and event-related potentials (ERP) obtained by placing two or more electrodes on the head to aid in diagnosis.